Merck says experimental skin disease drug meets main goal in mid-stage study

1

Sept 30 (Reuters) – Merck said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)